Blake Borgeson Sells 220,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $4.37, for a total value of $961,400.00. Following the transaction, the director owned 6,869,863 shares in the company, valued at approximately $30,021,301.31. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.26 during trading hours on Thursday, hitting $4.92. 19,765,769 shares of the stock traded hands, compared to its average volume of 29,378,354. The stock has a 50-day simple moving average of $5.12 and a 200 day simple moving average of $5.12. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a market cap of $2.56 billion, a P/E ratio of -2.73 and a beta of 0.94. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. Recursion Pharmaceuticals’s revenue was down 80.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.34) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Clear Creek Financial Management LLC boosted its position in Recursion Pharmaceuticals by 10.0% during the 2nd quarter. Clear Creek Financial Management LLC now owns 23,442 shares of the company’s stock worth $119,000 after acquiring an additional 2,127 shares during the period. TD Waterhouse Canada Inc. increased its holdings in shares of Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Recursion Pharmaceuticals by 16.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock worth $78,000 after purchasing an additional 2,219 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 8.0% during the third quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after purchasing an additional 2,221 shares during the period. Finally, Main Management ETF Advisors LLC grew its position in Recursion Pharmaceuticals by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock valued at $723,000 after purchasing an additional 2,328 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.